SPRING, Texas, July 16, 2024 (GLOBE NEWSWIRE) — Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS). The presentation titled “The RXR Nuclear Receptor Agonist Compound IRX4204 is a […] Read The Rest at :